- Oral presentation
- Open Access
O213. Low-level viraemia during treatment with darunavir/r monotherapy versus DRV/r + 2NRTIs in the MONET trial
Journal of the International AIDS Society volume 13, Article number: O19 (2010)
Patients with HIV RNA suppression below 50 copies/mL may still have HIV RNA detectable by more sensitive PCR assay techniques.
In the MONET trial, 256 patients with HIV RNA <50 copies/mL on current HAART, and no history of virological failure, switched to DRV/r 800/100 mg once daily, either as monotherapy (n=127) or with 2NRTI (n=129). HIV RNA was evaluated by the Roche Amplicor Ultrasensitive assay (lower detection limit=50 copies/mL), for all patient visits to Week 96. With this assay, "Optical Density=background" was used to assess whether HIV RNA was detectable or undetectable below 50 copies/mL.
Patients were 81% male, 91% Caucasian, and had median baseline CD4 count of 575 cells/uL. At the baseline visit, the percentage of patients with HIV RNA undetectable below 50 copies/mL (OD=background) was 80% in the DRV/r mono arm and 79% in the DRV/r + 2NRTI arm. The percentage with HIV RNA at different levels at the Week 96 visit is shown in Table 1 (observed data analysis)
Including all samples from patient visits from Week 4 to Week 96, HIV RNA was above 50 copies/mL in 69/1009 samples in the DRV/r monotherapy arm (50-400: 84%, 400-1000: 12%, >1000: 4%) and 47/1051 samples in the DRV/r + 2NRTI arm (50-400: 83%, 400-1000: 8.5%, >1000: 8.5%).
In this study for patients with HIV RNA <50 copies/mL at baseline, switching to DRV/r monotherapy showed similar levels of HIV RNA suppression to DRV/r + 2NRTIs, using more sensitive PCR assay techniques.
About this article
Cite this article
Clumeck, N., Arribas, J., Pulick, P. et al. O213. Low-level viraemia during treatment with darunavir/r monotherapy versus DRV/r + 2NRTIs in the MONET trial. JIAS 13, O19 (2010). https://doi.org/10.1186/1758-2652-13-S4-O19
- Lower Detection
- Lower Detection Limit
- Patient Visit
- Virological Failure
- Baseline Visit